Giuseppe Bertuglia

Giuseppe Bertuglia

Auto-generated profile, based on publicly available information

Giuseppe Bertuglia

SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di Torino Torino Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Blood
Verified
Journal Article
Closed access
PDF file
MDMattia D’aGostino
Mattia D’aGostino
GBGiuseppe Bertuglia
Giuseppe Bertuglia
DRDelia Rota-Scalabrini
Delia Rota-Scalabrini
ABAngelo Belotti
Angelo Belotti
SMSonia Morè
Sonia Morè
Francesca GayFrancesca Gay
Francesca Gay
The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRD-negative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow cytometry (sensitivity of 10−5) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and/or progression was analyzed in MRD-negative patients. A total of 306 of 474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD negativity, 185 of 306 (60%) patients were still MRD negative and progression free, 118 (39%) lost their MRD-negative status, and 3 patients (1%) died without progression. Amp1q vs normal (4-year CI, 63% vs 34), ≥2 concomitant high-risk cytogenetic abnormalities vs 0 (4-year CI, 59% vs 33%), circulating tumor cells at baseline (high vs low at 4-year CI, 62% vs 32%), and time-to-reach MRD negativity postconsolidation vs preconsolidation (4-year CI, 46% vs 35%) were associated with a higher risk of unsustained MRD negativity in a multivariate Fine-Gray model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs lenalidomide alone had a lower risk of unsustained MRD negativity (4-year CI, 20% vs 33%).

19 July 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
BZBachisio Ziccheddu
Bachisio Ziccheddu
CGClaudia Giannotta
Claudia Giannotta
MDMattia D’aGostino
Mattia D’aGostino
GBGiuseppe Bertuglia
Giuseppe Bertuglia
ESElona Saraci
Elona Saraci
ALAlessandra Larocca
Alessandra Larocca
Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However, a large fraction of patients inevitably relapse. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). We conducted an integrated analysis using whole-genome sequencing (WGS) and flow cytometry in patients with RRMM. WGS before and after treatment pinpointed genomic drivers associated with early progression, including RPL5 loss, APOBEC mutagenesis, and gain of function structural variants involving MYC and chromothripsis. Flow cytometry on 202 blood samples, collected every 3 months until progression for 31 patients, revealed distinct immune changes significantly impacting clinical outcomes. Progressing patients exhibited significant depletion of CD38-positive NK cells, persistence of T-cell exhaustion, and reduced depletion of regulatory T cells over time. These findings underscore the influence of immune composition and daratumumab-induced immune changes in promoting MM resistance. Integrating genomics and flow cytometry unveiled associations between adverse genomic features and immune patterns. Overall, this study sheds light on the intricate interplay between genomic complexity and the immune microenvironment driving resistance to Dara-Rd in patients with RRMM.

3 February 2025 in Hematological Oncology
Verified
Journal Article
Open access
EMEnrica Antonia Martino
Enrica Antonia Martino
DDDaniele Derudas
Daniele Derudas
ERElena Rossi
Elena Rossi
PSPaola Stefanoni
Paola Stefanoni
SMSilvia Mangiacavalli
Silvia Mangiacavalli
MGMassimo Gentile
Massimo Gentile
This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority were under 70 years old (60.8%), predominantly female (56.9%), and heavily pretreated, with 74.5% being triple‐class refractory (TCR); 32.1% of the 28 patients with cytogenetic data had high‐risk abnormalities. The overall response rate (ORR) was 56.9%, including 3 patients with stringent complete response (sCR), 4 with CR, and 7 with very good partial response (VGPR). Neither age, number of prior therapies, TCR status, nor time from Dara refractoriness to IsaPd initiation significantly affected response rates.Median progression‐free survival (PFS) was 5.8 months, with a 12‐month PFS probability of 30.6%. Baseline hemoglobin (Hb) levels were a key predictor of PFS: patients with Hb < 11.8 g/L had a 3.5‐fold increased risk of progression, with a median PFS of 4.6 months compared to 22 months in those with higher Hb.Median overall survival (OS) was 21.0 months, with a 12‐month OS probability of 63.4%. Lower Hb levels (< 11 g/L) were associated with a tenfold increased risk of mortality.Among the 28 patients who underwent FISH analysis, while no significant difference in mortality risk was observed, those with high‐risk cytogenetic abnormalities exhibited a nearly tenfold increased risk of disease progression.These results suggest that IsaPd offers a meaningful option for Dara‐R patients, with Hb levels serving as a critical predictor of both PFS and OS. However, PFS remains modest, underscoring the need for novel combination therapies.

31 May 2024 in Hematological Oncology
Verified
Journal Article
Closed access
EMEnrica Antonia Martino
Enrica Antonia Martino
SPSalvatore Palmieri
Salvatore Palmieri
MGMonica Galli
Monica Galli
DDDaniele Derudas
Daniele Derudas
RMRoberto Mina
Roberto Mina
MGMassimo Gentile
Massimo Gentile

11 March 2026 in ESMO Open
Verified
Journal Article
Open access
Francesca GayFrancesca Gay
Francesca Gay
GBG. Buda
G. Buda
MPM.T. Petrucci
M.T. Petrucci
NBNiccolò Bolli
Niccolò Bolli
MCM. Cea
M. Cea
Elena ZamagniElena Zamagni
Elena Zamagni
The treatment landscape of multiple myeloma (MM) has been revolutionized over the past two decades, leading to unprecedented deep and durable responses, prolonged survival, and improved quality of life. Nonetheless, MM is still an incurable disease, and many patients, especially those with high-risk cytogenetics, renal impairment, or early drug resistance, continue to face poor outcomes. Selinexor, the first-in-class, orally bioavailable selective inhibitor of exportin 1 (XPO1), has shown encouraging results in combination with other agents, and selinexor-based therapy has been approved for the treatment of relapsed/refractory MM, with selinexor-bortezomib-dexamethasone approved for patients with at least one prior line of therapy and selinexor-dexamethasone approved in the later-relapse setting. Notably, selinexor-based combinations have demonstrated consistent efficacy across different subgroups of patients, including those with triple-class refractory disease, renal dysfunction, high-risk cytogenetics, and prior anti-CD38 therapy. We herein provide an overview of selinexor, by describing its mechanism of action, potential interaction with other classes of drugs, novel combinations under investigation, and its role in treatment sequencing, by discussing latest results and potential strategies to mitigate toxicities, increase efficacy, and implement treatment adherence in MM. Overall, selinexor continues to represent a valuable option, especially for patients who are ineligible to receive T-cell-redirecting therapies, or difficult-to-treat patient subgroups, where alternative strategies remain limited. Meanwhile, further data on the use of selinexor-based combinations in different settings are eagerly awaited, to help clarify its role and address persistent unmet clinical needs.

20 November 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
GBGiulia Benevolo
Giulia Benevolo
GBGiuseppe Bertuglia
Giuseppe Bertuglia
SBSara Bringhen
Sara Bringhen
FMFrancesca Maletta
Francesca Maletta
BBBENEDETTO BRUNO
BENEDETTO BRUNO